BZDS1901 special access scheme launch in China
Filed with ASX · · 4 pages · English
Summary by 6ix AI
This approval follows an independent assessment of the therapy's safety and efficacy, offering new hope to patients with limited treatment options. The treatment will be administered at Ruijin Hospital in Hainan, and AdAlta will gather real-world data on patient outcomes to support its product development.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from AdAlta
- EW-001 IIT study overall survival update
- 2 year survival milestone for EW-001 patient
- Oktopi AI collaboration for research efficiency
- Second BZDS1901 milestone paid
- Regulatory advisors appointed for BZDS1901
Later from AdAlta
- Oribiotech deal validates AdAlta manufacturing strategy
- US FDA grants EW-001 pre-IND meeting
- China Representative Office opens
- EW-001 JDC milestone approvals
- RDTI receipt, Advanced Overseas Finding
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta